New muscle scanner could help seniors stay independent longer

NCT ID NCT06963359

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new technology (HD-sEMG) that monitors muscle signals to better diagnose sarcopenia—a condition where older adults lose muscle mass and strength. Researchers will enroll 846 people aged 75 and older who are hospitalized and at risk for sarcopenia. The goal is to see if this technology can accurately identify those with the condition, helping doctors intervene earlier to prevent falls and loss of independence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital Bichat, APHP

    RECRUITING

    Paris, 75018, France

  • Hôpital Charles Foix, APHP

    RECRUITING

    Ivry-sur-Seine, 94205, France

  • Hôpital Charles Foix, APHP

    RECRUITING

    Ivry-sur-Seine, 94205, France

  • Hôpital Charles Foix, APHP

    RECRUITING

    Ivry-sur-Seine, 94205, France

  • Hôpital Corentin Celton, APHP

    RECRUITING

    Issy-les-Moulineaux, 92130, France

  • Hôpital Corentin Celton, APHP

    RECRUITING

    Issy-les-Moulineaux, 92130, France

  • Hôpital Rothschild, APHP

    RECRUITING

    Paris, 75012, France

  • Hôpital Rothschild, APHP

    RECRUITING

    Paris, 75012, France

  • Hôpital Saint-Antoine, APHP

    RECRUITING

    Paris, 75012, France

  • Hôpital Tenon, APHP

    RECRUITING

    Paris, 75020, France

  • Unité d'Explorations fonctionnelles du sujet âgé - Hôpital Charles Foix

    NOT_YET_RECRUITING

    Ivry-sur-Seine, 94205, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.